Cancer Genetics, which offers personalized genomic tests to improve the diagnosis and treatment of cancer, postponed its IPO on Thursday. The Rutherford, NJ-based company was founded in 1999 and booked $3 million in sales for the 12 months ended 3/31/2012. William Blair and Baird were set to be the joint bookrunners on the deal.
